BCRX - BioCryst Pharmaceuticals: BCX9930 Results In PNH Patients An Important Near-Term Catalyst

I devoted a lot of attention to BioCryst Pharmaceuticals (BCRX) over the last 10 months but have not invested yet. That’s because of the specific set of circumstances the company was in over that time. First, I believed that the BCX7353 (berotralstat) phase 3 readout had more risk than reward and I noted I would be a buyer under the right set of circumstances – decent data and the removal of the financing overhang. Unsurprisingly, the market reacted badly to berotralstat not living up to potential and the stock plunged after the readout

Read more ...